01—Abstract
Summary
Summary of the 8-K filed November 4, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2026 results for the quarter ended September 26, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K.
Third-quarter revenue was $982.7 milliona, down from $1,004.9 million a year earlier, mainly due to the May 2026 divestitures; on an organic basis revenue rose 4.7%. GAAP earnings per diluted share were $6.86, boosted by a $245.6 million, or $5.06 per share, benefit from the reversal of acquired tax reserves. Non-GAAP diluted EPS was $3.09, up 27.2% from $2.43.
The company raised its 2026 guidance. Organic revenue growth is now expected to be at least +1.5% (previously 0.0% to 1.0%), and non-GAAP EPS is now $11.35 to $11.55b (previously $11.15 to $11.45). GAAP EPS guidance rose to $8.15 to $8.35 from $3.05 to $3.35.
Management attributed the increase mainly to better-than-expected DSA segment performance and a lower tax rate. Management also highlighted the 2026 Investor Day unveiling of its Pathway to Purpose strategy and Create the Future initiative. Segment results were mixed.
DSA revenue was $596.3 millionc, with organic growth of 5.9% and non-GAAP operating margin of 26.8%. Manufacturing Solutions revenue was $178.9 million, with organic growth of 7.4% and non-GAAP operating margin of 38.6%. Research Models and Services revenue was $207.5 million, with organic revenue down 0.6% and non-GAAP operating margin of 24.4%.
02—Key points
Key Highlights
- Third-quarter revenue of $982.7 million declined 2.2% year over year, primarily due to the May 2026 divestitures; organic revenue grew 4.7%.
- GAAP diluted EPS of $6.86 includes a $5.06 per share benefit from reversing acquired tax reserves; non-GAAP diluted EPS rose 27.2% to $3.09.
- Non-GAAP operating margin rose 330 basis points to 23.0%, and GAAP operating margin rose 730 basis points to 20.6%.
- 2026 guidance raised: organic revenue growth at least +1.5% (from 0.0% to 1.0%) and non-GAAP EPS of $11.35 to $11.55 (from $11.15 to $11.45).
- GAAP EPS guidance increased to $8.15 to $8.35 from $3.05 to $3.35, driven primarily by the tax reserve reversal.
- DSA segment organic revenue grew 5.9%, with GAAP operating margin of 28.9% and non-GAAP operating margin of 26.8%.
- Nine-month non-GAAP operating margin was 19.9%, reflecting the impact of divestitures, including the CDMO and Cell Solutions businesses.
03—Questions
Frequently Asked Questions
Why did reported revenue decline while organic revenue grew?
Reported revenue fell 2.2% to $982.7 million mainly because of the May 2026 divestitures, including the CDMO and Cell Solutions businesses and certain European Discovery Services sites. Organic revenue, which excludes acquisitions, divestitures, and foreign currency effects, rose 4.7%, driven by Manufacturing and DSA.
How much of the GAAP earnings came from one-time items?
The GAAP net income and EPS increases included a benefit of $245.6 million, or $5.06 per share, from reversing acquired tax reserves after newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. The DSA segment also recorded a $44.6 million benefit from the same reversal.
What changed in the 2026 outlook?
Organic revenue growth guidance is now at least +1.5%, up from 0.0% to 1.0%. Non-GAAP EPS guidance is $11.35 to $11.55, up from $11.15 to $11.45, and GAAP EPS guidance is $8.15 to $8.35, up from $3.05 to $3.35. Management cited third-quarter outperformance, mainly in DSA, and a lower tax rate.
What drove the margin improvement?
Non-GAAP operating margin rose to 23.0% from 19.7%, mainly due to the benefit of the CDMO divestiture and operating leverage from higher safety assessment volume. Within segments, Manufacturing's non-GAAP margin rose to 38.6% from 26.7%, while RMS's fell to 24.4% from 25.0% due to unfavorable revenue mix.
04—Continue